These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 31859415)

  • 21. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
    Adamkewicz JI; Chen DC; Paz-Priel I
    Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Emicizumab, a bispecific antibody mimicking factor VIII: a novel alternative therapy for hemophilia A with inhibitors].
    Nogami K
    Rinsho Ketsueki; 2019; 60(5):475-479. PubMed ID: 31168016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emicizumab prophylaxis in haemophilia A with inhibitors: Three years follow-up from the UK Haemophilia Centre Doctors' Organisation (UKHCDO).
    Wall C; Xiang H; Palmer B; Chalmers E; Chowdary P; Collins PW; Fletcher S; Hall GW; Hart DP; Mathias M; Sartain P; Shapiro S; Stephensen D; Talks K; Hay CRM;
    Haemophilia; 2023 May; 29(3):743-752. PubMed ID: 36811304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.
    Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD
    Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emicizumab treatment: Impact on coagulation tests and biological monitoring of haemostasis according to clinical situations (BIMHO group proposals).
    Nougier C; Jeanpierre E; Ternisien C; Proulle V; Hezard N; Pouplard C; Lasne D;
    Eur J Haematol; 2020 Dec; 105(6):675-681. PubMed ID: 32668090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A.
    Díaz-Ricart M; Isola IM; Escolar G
    Drugs Today (Barc); 2018 Oct; 54(10):591-600. PubMed ID: 30398480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
    Brophy DF; Martin EJ; Kuhn J
    Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061
    [No Abstract]   [Full Text] [Related]  

  • 28. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays.
    Kizilocak H; Marquez-Casas E; Malvar J; Carmona R; Young G
    Haemophilia; 2021 Sep; 27(5):730-735. PubMed ID: 34115433
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.
    Oldenburg J; Mahlangu JN; Bujan W; Trask P; Callaghan MU; Young G; Asikanius E; Peyvandi F; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Xu J; Windyga J; Shima M; von Mackensen S
    Haemophilia; 2019 Jan; 25(1):33-44. PubMed ID: 30427582
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.
    Batsuli G; Zimowski KL; Tickle K; Meeks SL; Sidonio RF
    Haemophilia; 2019 Sep; 25(5):789-796. PubMed ID: 31373431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET.
    Coppola A; Castaman G; Santoro RC; Mancuso ME; Franchini M; Marino R; Rivolta GF; Santoro C; Zanon E; Sciacovelli L; Manca S; Lubrano R; Golato M; Tripodi A; Rocino A;
    Haemophilia; 2020 Nov; 26(6):937-945. PubMed ID: 33094880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
    Oldenburg J; Mahlangu JN; Kim B; Schmitt C; Callaghan MU; Young G; Santagostino E; Kruse-Jarres R; Negrier C; Kessler C; Valente N; Asikanius E; Levy GG; Windyga J; Shima M
    N Engl J Med; 2017 Aug; 377(9):809-818. PubMed ID: 28691557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.
    Doshi BS; Witmer CM
    Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra
    Susen S; Gruel Y; Godier A; Harroche A; Chambost H; Lasne D; Rauch A; Roullet S; Fontana P; Goudemand J; de Maistre E; Chamouard V; Wibaut B; Albaladejo P; Négrier C
    Haemophilia; 2019 Sep; 25(5):731-737. PubMed ID: 31294904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 36. Emicizumab assay evaluations and results from an Australian field study of emicizumab measurement.
    Kershaw G; Dix C; Chen VM; Cai N; Khoo TL
    Pathology; 2022 Oct; 54(6):755-762. PubMed ID: 35577608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emicizumab for the treatment of haemophilia A: a narrative review.
    Franchini M; Marano G; Pati I; Candura F; Profili S; Veropalumbo E; Masiello F; Catalano L; Piccinini V; Vaglio S; Pupella S; Liumbruno GM
    Blood Transfus; 2019 May; 17(3):223-228. PubMed ID: 31246563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.
    Ebbert PT; Xavier F; Seaman CD; Ragni MV
    Haemophilia; 2020 Jan; 26(1):41-46. PubMed ID: 31746522
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
    Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
    Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.